Ripertamab plus eltrombopag for ITP after steroids fail
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests adding a new drug (ripertamab) to a standard ITP treatment (eltrombopag) for patients whose platelet count hasn't improved with steroids. The goal is to see if the combination works better at raising platelet counts and lowering bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary immune thrombocytopenia (ITP) and are between 18 and 80 years old.
- You have had your bone marrow tested to confirm ITP and rule out other causes.
- Your platelet count dropped below 30 × 10^9/L after trying or stopping steroid therapy.
- You have normal blood clotting (PT/INR and APTT tests) and a healthy number of neutrophils and hemoglobin.
- You have no history of cancer, major heart problems, active infections, or other bleeding disorders.
- You have not used certain ITP treatments (like IVIG, TPO receptor agonists, or rituximab) in the last 28 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—avatrombopag and all-trans retinoic acid—in adults with persistent or chronic immune thrombocytopenia (ITP) whose platelet levels stay low despite prior treatments. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
This trial tests two ways to raise platelets for people with immune thrombocytopenia (ITP) who did not respond well to a short course of the platelet-boosting drug rhTPO. One group gets a higher dose of rhTPO, the other switches to a different oral medication, eltrombopag. The goal is to see which approach works better to increase platelet counts safely.
This trial tests a two-step approach for adults with severe ITP: first a growth factor injection (rhTPO), then a pill (eltrombopag). The goal is to see if this sequence works better than steroids alone to raise platelet counts safely.
Hear when a new ITP - Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.